Access has focused its Cobalamin product development program on the oral delivery of insulin and human growth hormone. A new Cobalamin-coated insulin-containing nanoparticle formulation delivered orally, provided a pharmacological response greater than 80% of that achieved by insulin delivered subcutaneously.
The result suggested a substantial oral bioavailability, indicating that the formulation has the potential for clinical development and commercialisation. Adaptation of this technology has provided a Cobalamin human growth hormone formulation that has demonstrated good efficacy, represented by more than 25% improvement in weight gain, when given orally in an established animal model.
Access continues to move both products towards clinical development, and plans to submit an additional patent application to protect the improvements to the technology. The company is developing its Cobalamin technology under multiple collaborative agreements, and is in discussion with other companies regarding the application of the Cobalamin technology to other active drug candidates.
Phillip Wise, vice president of business development and strategy at Access, said: “While Access continues to explore collaborations on multiple applications of our technology, our Cobalamin oral insulin product continues to be the focus of current collaborative work. We continue to work with two companies testing Cobalamin oral insulin in multiple animal models. Meanwhile, we are pursuing options with other companies with the goal of initiating a proof-of-concept in man study.”